Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02098473 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
A Phase 2 study of Eosinophilic Esophagitis, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT02098473 is a Phase 2 study of Eosinophilic Esophagitis that has completed, run by Celgene. The registered enrollment target is 100 participants, below the 862-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT02098473, a Phase 2 study of Eosinophilic Esophagitis, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the effective dose(s) of RPC4046 in the treatment of Eosinophilic Esophagitis (EoE). This trial consists of two phases: 16 weeks of double-blind treatment and 52 weeks of open-label extension.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RPC4046
Study Locations (20)
Arizona
- Mayo Clinic - Arizona - Scottsdale
- Desert Sun Clinical Research, LLC - Tucson
California
- Alliance Clinical Research - Oceanside
- Precision Research Institute, LLC - San Diego
Florida
- University of Florida - Gainesville
- Borland-Groover Clinic - Jacksonville
Illinois
- Northwestern University-Feinberg School of Medicine - Chicago
- Southwest Gastroenterology - Oak Lawn
Maryland
- Gastroenterology and Hepatology Service Walter Reed National Military Medical Center - Bethesda
- Metropolitan Gastroenterology Group Chevy Chase Clinical Research - Chevy Chase
Colorado
- University of Colorado School of Medicine - Aurora
Connecticut
- Connecticut Clinical Research Foundation - Bristol
Georgia
- Children's Center for Digestive Healthcare - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2014-08-31 |
| Est. Completion | 2017-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02098473
The ClinicalTrials.gov registry entry for NCT02098473 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 862-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (88% lower). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Eosinophilic Esophagitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02098473 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT02098473 about?
NCT02098473 is a clinical study titled "Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis". The purpose of this study is to determine the effective dose(s) of RPC4046 in the treatment of Eosinophilic Esophagitis (EoE). This trial consists of two phases: 16 weeks of double-blind treatment and 52 weeks of open-label extension.
What is the current status of trial NCT02098473?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2014-08-31. Estimated completion is 2017-01-30.
What conditions does trial NCT02098473 study?
This clinical trial studies the following conditions: Eosinophilic Esophagitis.
What interventions are being tested in trial NCT02098473?
The interventions under investigation include: Placebo (DRUG), RPC4046 (DRUG).
Who is sponsoring clinical trial NCT02098473?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02098473 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Esophagitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
RECRUITING · Phase 2
-
Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE
RECRUITING · Phase 2
-
Zemaira Eosinophilic Esophagitis Pilot Study
RECRUITING · Phase 2
-
Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years
COMPLETED · Phase 2
-
A Study of Flovent in Patients With Eosinophilic Esophagitis
COMPLETED · Phase 2
-
Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.